Financial Performance - The company expects a net profit of approximately 30 million yuan for the year 2024, marking a turnaround from a loss in the previous year[3] - The net profit attributable to the parent company, excluding non-recurring gains and losses, is estimated to be around 6 million yuan for 2024[3] - In the previous year, the company reported a net loss of 35.08 million yuan attributable to the parent company[4] - The total profit for the previous year was -30.36 million yuan, indicating a significant improvement in the current year's performance[4] Sector Performance - The growth in the health product terminal sector is attributed to stable sales growth across various online platforms in 2024[5] - The investment and financing sector benefited from a lawsuit victory, leading to changes in the profit and loss of a wholly-owned subsidiary[5] Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast[6] - The financial data provided is preliminary and has not been audited by an accounting firm, with the final figures to be disclosed in the official 2024 annual report[7]
ST交昂(600530) - 2024 Q4 - 年度业绩预告(更正)